{"id":"axs-05","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Sedation"}]},"_chembl":{"chemblId":"CHEMBL5861098","moleculeType":null,"molecularWeight":"533.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug combines dextromethorphan (a sigma-1 receptor agonist and NMDA antagonist) with bupropion (a norepinephrine-dopamine reuptake inhibitor). This combination is designed to provide rapid-acting antidepressant effects through multiple mechanisms: bupropion increases norepinephrine and dopamine levels, while dextromethorphan acts on sigma-1 receptors and NMDA receptors to enhance neuroplasticity and reduce depressive symptoms more quickly than traditional antidepressants.","oneSentence":"AXS-05 is a combination of dextromethorphan and bupropion that enhances serotonergic and noradrenergic neurotransmission while modulating NMDA receptor activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:24.827Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder (approved)"},{"name":"Treatment-resistant depression (approved)"}]},"trialDetails":[{"nctId":"NCT06736509","phase":"PHASE3","title":"An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study","status":"TERMINATED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2024-11-21","conditions":"Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor","enrollment":139},{"nctId":"NCT04634669","phase":"PHASE2","title":"Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)","status":"TERMINATED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2020-09-23","conditions":"Treatment Resistant Depression, Major Depressive Disorder","enrollment":181},{"nctId":"NCT04947553","phase":"PHASE3","title":"A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2021-06-17","conditions":"Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor","enrollment":456},{"nctId":"NCT05557409","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2022-09-06","conditions":"Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation","enrollment":408},{"nctId":"NCT06223880","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2023-12-27","conditions":"Major Depressive Disorder","enrollment":350},{"nctId":"NCT04797715","phase":"PHASE3","title":"Assessing Clinical Outcomes in Alzheimer's Disease Agitation","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2020-12-31","conditions":"Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor","enrollment":178},{"nctId":"NCT03226522","phase":"PHASE2, PHASE3","title":"Addressing Dementia Via Agitation-Centered Evaluation","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2017-07-13","conditions":"Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor","enrollment":366},{"nctId":"NCT03471767","phase":"PHASE2","title":"AXS-05 Phase II Trial on Smoking Behavior","status":"COMPLETED","sponsor":"James Davis","startDate":"2018-03-25","conditions":"Smoking Cessation, Smoking, Cigarette, Nicotine Dependence","enrollment":58},{"nctId":"NCT04039022","phase":"PHASE3","title":"Open-Label Safety Study of AXS-05 in Subjects With Depression","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-07-08","conditions":"Major Depressive Disorder, Treatment Resistant Depression, Depression","enrollment":876},{"nctId":"NCT04019704","phase":"PHASE3","title":"A Trial of AXS-05 in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-06-20","conditions":"Depression, Major Depressive Disorder","enrollment":327},{"nctId":"NCT04608396","phase":"PHASE2","title":"Mechanistic Evaluation of Response in TRD (MERIT)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2020-08-13","conditions":"Treatment Resistant Depression, Major Depressive Disorder","enrollment":44},{"nctId":"NCT03595579","phase":"PHASE2","title":"Assessing Symptomatic Clinical Episodes in Depression","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2018-05-30","conditions":"Major Depressive Disorder","enrollment":97},{"nctId":"NCT04971291","phase":"PHASE2","title":"An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients","status":"UNKNOWN","sponsor":"Axsome Therapeutics, Inc.","startDate":"2021-04-14","conditions":"Major Depressive Disorder, Treatment Resistant Depression","enrollment":312},{"nctId":"NCT02741791","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2016-03","conditions":"Treatment Resistant Major Depressive Disorder","enrollment":312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bupropion/dextromethorphan"],"phase":"marketed","status":"active","brandName":"AXS-05","genericName":"AXS-05","companyName":"Axsome Therapeutics, Inc.","companyId":"axsome-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AXS-05 is a combination of dextromethorphan and bupropion that enhances serotonergic and noradrenergic neurotransmission while modulating NMDA receptor activity. Used for Major depressive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}